Suzuki Masami, Kato Chie, Kato Atsuhiko
Research Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan.
J Toxicol Pathol. 2015 Jul;28(3):133-9. doi: 10.1293/tox.2015-0031. Epub 2015 Jun 15.
Antibodies can swiftly provide therapeutics to target disease-related molecules discovered in genomic research. Antibody engineering techniques have been actively developed and these technological innovations have intensified the development of therapeutic antibodies. From the mid-1990's, a series of therapeutic antibodies were launched that are now being used in clinic. The disease areas that therapeutic antibodies can target have subsequently expanded, and antibodies are currently utilized as pharmaceuticals for cancer, inflammatory disease, organ transplantation, cardiovascular disease, infection, respiratory disease, ophthalmologic disease, and so on. This paper briefly describes the modes of action of therapeutic antibodies. Several non-clinical study results of the pathological changes induced by therapeutic antibodies are also presented to aid the future assessment of the toxic potential of an antibody developed as a therapeutic.
抗体能够迅速提供治疗药物,以靶向基因组研究中发现的与疾病相关的分子。抗体工程技术一直在积极发展,这些技术创新加速了治疗性抗体的开发。从20世纪90年代中期开始,一系列治疗性抗体相继推出,目前已应用于临床。治疗性抗体能够靶向的疾病领域随后不断扩大,目前抗体被用作治疗癌症、炎症性疾病、器官移植、心血管疾病、感染、呼吸系统疾病、眼科疾病等的药物。本文简要描述了治疗性抗体的作用模式。还介绍了治疗性抗体诱导的病理变化的一些非临床研究结果,以帮助未来评估作为治疗药物开发的抗体的潜在毒性。